Welcome to Inogen’s Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today, November 7, 2024. I would now like to turn the call over to Ryan Peterson, Investor Relations.

Thank you all for participating in today’s call. Joining me are President and CEO, Kevin Smith; and CFO, Mike Bourque. Earlier today, Inogen released financial results for the third quarter of 2024. This earnings release is available in the Investor Relations section of the company’s website, along with a supplemental financial package. As a reminder, the information presented today will include forward-looking statements, including, without limitation, statements about our growth prospects and strategy for 2024 and beyond, expectations related to our financial results for the full year 2024, progress of our strategic initiatives, including innovation, our expectations regarding the market for our products, on our business and supply and demand for our products in both the short-term and long-term. The forward-looking statements in this call are based on information currently available to us as of today’s date, November 7, 2024. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary, and we disclaim any obligations to update these forward-looking statements, except as may be required by law. We have posted historical financial statements and our investor presentations in the Investor Relations section of the company’s website. Please refer to these files for more detailed information. During the call, we will also present certain financial information on a non-GAAP basis. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash items and other expenses that are not indicative of Inogen’s core operating results. Management uses non-GAAP measures internally to understand, manage, and evaluate our business and make operating decisions. Reconciliations between U.S. GAAP and non-GAAP results are presented in tables within our earnings release. With that, I will turn the call over to Inogen’s President and CEO, Kevin Smith.

Good afternoon and thank you for joining our third quarter 2024 conference call. During today’s call, I will review our third quarter performance and provide an update on our progress towards our three strategic priorities, driving topline growth, advancing our path to profitability and expanding our innovation pipeline. I will then turn the line to Mike for a full review of our financials and outlook. I am pleased to share that we are making great progress against our strategic initiatives, beginning with our progress on driving topline growth. In the third quarter, we delivered on this objective by achieving $89 million in total revenue, reflecting 6% year-over-year growth. Our performance was led by strong POC sales through our business-to-business channels, where we drove over 20% year-over-year revenue growth for the second consecutive quarter. We continue to expand our relationships with new and existing customers as patients and providers increasingly recognize the benefits that our solutions provide over other oxygen therapies and appreciate our quality, ease of servicing and eight-year service life. In particular, we are having success taking and expanding share within the accounts of some of our largest customers. Turning to our direct-to-consumer sales channel, we saw year-over-year declines as we continue to operate with a downsized and streamlined sales force. Although, our revenue is down, we are pleased that this channel is becoming more profitable as a result of our cost structure and careful management. As we complete our first full year with a smaller team and move into 2025, we anticipate better year-over-year performance. DTC is a core part of our business model and we are working diligently to bring it back to growth. As part of these efforts within the DTC business, we continue to advance our previously announced hospital and patient-first pilot programs. On the…

Thank you, Kevin, and good afternoon, everyone. Unless otherwise noted, all financial comparisons are to the prior year comparable period. Total revenue for the third quarter of 2024 was $88.8 million, an increase of 5.8% compared to the prior year. The increase was primarily driven by higher domestic and international business-to-business sales, partially offset by lower direct-to-consumer sales and rental revenue. For the third quarter, foreign exchange had a negative 20 basis points impact on total revenue and a negative 70 basis points impact on international revenue. Looking at third quarter revenue on a more detailed basis, direct-to-consumer sales decreased 23.2% to $19.2 million from $25.1 million in the prior period, as we continued to operate with a smaller and more efficient team. As Kevin mentioned, we look forward to completing our first full year with this team in place and positioning the D2C business for better performance into the years ahead. Domestic business-to-business revenue increased 35.1% to $23.4 million versus $17.3 million in the comparable period, driven by increased demand from new customers and resellers. International business-to-business revenue increased 26.2% to $32.3 million, compared to $25.6 million in the prior period, primarily driven by increased demand with new and existing customers. Rental revenue decreased 13.1% to $13.9 million from $16 million in the prior period, primarily driven by continued lower average billing rates due to the mixed shift to private payers. Now I want to discuss our gross margins. Total gross margin was 46.5%, increasing 630 basis points from the same period in the prior year, primarily driven by lower premiums paid for raw material components, partially offset by sales channel mix. As shared on our second quarter call, we expect gross margins to be in the low-to-mid 40s in the second half of the year. Sales revenue gross…

In a week from now, I will have had the privilege of being the CEO of Inogen for a year. And while we have just recently cemented our leadership team in place, I am thrilled with the progress we have made thus far. There’s much work to be done, but our team is performing at a high level and I’m very optimistic for what the end of 2024 and 2025 holds in store for Inogen. With that, I will open it up for questions. Operator?

Thank you. [Operator Instructions] Thank you. Our first question comes in line of Robbie Marcus with JPMorgan. Please proceed.

Hi. This is actually Rohin on for Robbie. Thanks for taking our question. Just maybe starting with DTC, I was hoping you could give a little bit more color on the sales force and specifically just around the size and productivity heading into 2025. Just want to -- and also kind of going off of that, just want to understand what the strategy is, given the downside sales force to get the business back to growth, potentially next year and beyond?

Thanks, Rohin. I’ll start with that. This is Kevin. I appreciate the question. The -- yeah, when we look at the size of the sales force on a year-over-year basis, we are down, which is as planned, as we talked about in some of the previous calls. We are looking at increased productivity per rep compared to some of the recent historic levels and that’s a positive. We start to see that trend up. And as we’re looking outward on the DTC, remember, that’s one where we have focused on the patient-first initiative, as well as making sure that we’re right-sizing and evaluating how we’re spending our advertising dollars to continue to build that up. So this has been a rebase year for DTC. We’ve been through that third quarter in the middle of that rebase and so we have positive outlooks for this going forward. But we won’t be getting into that full rollout of the patient-first program until we hit until the first half of next year.

Got it. And it was also nice to see some topline momentum in the quarter, as well as another quarter of positive free cash flow. So I just wanted to ask about your expectations for both the top and bottomline into 2025, and specifically just around cash flow generation from here. Do you think this is something that’s probably more sustainable year on out and what are some of the puts and takes?

Hi, Rohin. This is Mike. Yeah. In terms of cash generation, clearly we’re really happy with the fact that we have the second consecutive quarter of positive cash generation. I think a lot of this really kind of gets back to, as Kevin talked about, executing in our strategic initiatives, looking at that topline growth, path and profitability, the innovation pipeline. But getting to those first two, I guess, really we’ve been talking about investing in the business wisely, smart, at the same time diligently managing our P&L, ensuring we’re generating profitable growth, higher gross margins. Kevin also talked about some of the things we’re doing on the cost of goods sold reduction initiatives, some of the things that we’re looking at there, and really just getting back to what we said about managing our cost structure and CapEx, always looking at ways to manage our working capital and improve cash flow. In terms of if you’re looking at kind of a forward look and we’re not guiding to where we expect our cash to be, but what I can say is if you’re looking at kind of where are we from a perspective of quarter-over-quarter, we’re going into Q4, which is typically a seasonally impacted, particularly in D2C. We’re expecting to see and we’ve talked about that a little bit more, of an impact of generate -- more difficulty generating some leads as a result of some of the advertising experiences that we’re seeing and expecting to see. So I guess if you look at that, and you look at the positive EBITDA for two quarters, positive cash for two quarters, looking at our two strongest quarters, which are typically Q2 and Q3. So again, we’ll continue to focus in on making sure we’re investing money into the business, doing it in a smart way, controlling our cost structure, managing OpEx, managing CapEx.

Great. Thank you.

Thank you. Our next question comes from the line of Mike Matson with Needham. Please proceed.

Yeah. Thanks. So I guess just following up on the commentary around the DTC, rep headcount. So I guess, just trying to figure out when that would sort of stabilize. In other words, like, what quarter will be where you’re lapping the year-over-year change in that headcount is basically flat. Like how far out is that from like the third quarter that you just reported?

Yeah. So as we look where we are in the -- on the third quarter and going forward, we feel like we’ve got a pretty good handle on the rep count and what it takes to be profitable from that standpoint. This channel we are seeing improved productivity. As I mentioned, we’re seeing improved profitability coming from the channel and the number of reps that we have in there right now, we feel pretty good as I was saying about that. So, in a year-on-year basis, you’ll still see us going into the beginning of next year, probably, being a little bit under where we started, but getting into the -- getting that back at the middle part of next year where we see it continue to be steady.

Okay. Got it. All right. And then just on Simeox, I wanted to see if you could clarify what you said, because I thought you said something that you’re talking to FDA and they’ll provide an update upon clearance. So…

Yeah.

… my interpretation of that and this might be wrong, but would be that you’ve submitted something for clearance and clearance, but even the word clearance supplies a 5, 10-K I think, but I don’t know. Am I understanding that correctly or am I missing something?

Yeah. In generally speaking there, what you, certainly, we’ve been asked a lot about the timing on Simeox and so what we’ve been doing is giving the indication and the sharing that we’ve had positive interactions with the FDA. We have not illustrated any further what the nature of that is and we haven’t confirmed that we filed with the FDA. But I said in some of our previous call that we are going to be providing an update once we do have that regulatory pathway completed. In other words that the FDA has given us clearance, but Mike, I know we’ve talked also about -- yeah, about the financial statements and how that kind of points to that positive outlook.

Yes, Kevin. And so I can add just a little bit of that. I think folks understand that. We do have an earn-out agreement with the Physio-Assist acquisition. We disclosed this information at 10-Q. So if you kind of get trying to get a general idea in terms of how things are going, that earn-out is maxed at $13 million and we continue to accrue we’re at about $11.9 million through Q3. So, I guess, all I could say would be that, when you see the accrual continuing to increase, it just means we’re progressing. But it’s, as Kevin said, we’ll talk more about that when we actually get the clearance. But I think that gets an indication of kind of how we’re moving forward with this.

Okay. All right. And then just, I guess, Rove 4, I mean, it seems like a great product based on the specs. So, I mean, how is that being received across the different channels? And is that something that’s more -- it seems like that’s more geared probably to DTC side than the B2B side, but let me know if that’s wrong?

No. That’s a -- yeah, that’s pretty spot on there. And it’s a -- so the Rove 4, we do see that being an influential piece of our business as we’re going forward, but that’ll be more of a 2025 versus a 2024 since we’ve just launched it. But as you said, the play for that will be in the U.S. market. It’ll be more interesting in the DTC side. So if you think about that, we’re able to capture patients earlier in their disease state, take them on that first product, that first in the road series, the Rove 4, for a little bit longer since it’s a, it has an additional setting and it’s a characteristics versus the versus the G4. So there’s an opportunity there also, as we initiate patients, treatment with the Rove 4 that if they do well, if they live long, but their disease progresses, then we could upgrade them in the future to the Rove 6. So that’s a -- that we believe is an interesting play for it for us. On the B2B side, it would be more in the international than it would be for the domestic B2B business, because in the B2B side, the HMEs, they tend to want to get a patient on one POC and have them stay on that POC for a longer period of time or reduces their investment. But the international markets have a little bit of a different view on that.

Okay. Thank you.

Thank you. There are no further questions at this time. I’d like to conclude the call. Thank you everyone for your participation. You may now disconnect your lines.